Recent Quotes (30 days)

You have no recent quotes
chg | %

Bionomics Ltd  

(Public, ASX:BNO)   Watch this stock  
Find more results for ASX: BNO
0.440
-0.020 (-4.35%)
Oct 20 - Close
ASX data delayed by 20 mins - Disclaimer
Currency in AUD
Range 0.43 - 0.47
52 week 0.31 - 0.50
Open 0.47
Vol / Avg. 603,036.00/181,627.00
Mkt cap 212.10M
P/E     -
Div/yield     -
EPS -0.01
Shares 481.46M
Beta     -
Inst. own     -
Sep 12, 2017
Bionomics Ltd at Rodman & Renshaw Global Investment Conference
Aug 16, 2017
Preliminary 2017 Bionomics Ltd Earnings Release
  

Key stats and ratios

Q2 (Jun '17) 2017
Net profit margin 18.30% -36.28%
Operating margin -9.74% -29.35%
EBITD margin - -19.98%
Return on average assets 7.18% -7.76%
Return on average equity 15.34% -15.95%
Employees 140 -
CDP Score - -

Address

31 Dalgleish St
THEBARTON, SA 5031
Australia
+61-8-83546100 (Phone)
+61-8-83546199 (Fax)

Website links

Description

Bionomics Limited is a clinical-stage biopharmaceutical company engaged in discovery and development of drug candidates focused on the treatment of central nervous system (CNS) disorders and cancer by using its platform technologies. The Company's segments include Drug discovery and development, and Contract services. The Drug discovery and development segment includes the discovery, development and commercialization of compounds to match a target product profile. The Contract services segment includes the provision of scientific services on a fee for service basis to both external and internal customers. Its product candidates include BNC210, BNC375, BNC101 and BNC105. The Company provides treatments for CNS disorders, such as anxiety, depression and Alzheimer's Disease. Its oncology approach targets cancer stem cell therapies in solid tumors. Its technologies include ionX and MultiCore. It operates in three geographical areas, such as Australia, France and the United States.

Officers and directors

Deborah Rathjen Ph.D. Chief Executive Officer, Managing Director, Executive Director
Steve Lydeamore Chief Financial Officer
Jens D. Mikkelsen Chief Scientific Officer
Tony Colasin Chief Business Officer
Robert Corringham M.D. Chief Medical Officer
Jack Moschakis Company Secretary , Legal Counsel
Errol B. De Souza Ph.D. Non-Executive Chairman of the Board
Age: 63
Alan David Fisher Non-Executive Director
Peter J. Turner Non-Executive Director
David Ian Wilson Non-Executive Director